SciSparc (SPRC) Total Debt (2018 - 2025)
SciSparc (SPRC) posted Total Debt of $356000.0 for Q4 2025, up 95.6% sequentially from $182000.0 in Q2 2025, and down 91.57% YoY from $4.2 million in Q4 2024.
SciSparc (SPRC) Total Debt (2018 - 2025) Analysis & Trends
SciSparc has reported Total Debt for 5 years, with the latest figure at $356000.0 in Q4 2025.
- Quarterly Total Debt fell 91.57% year-over-year to $356000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $356000.0 (down 91.57% YoY) and the FY2025 annual result came in at $356000.0, down 91.57% from the prior year.
- Total Debt grew to $356000.0 in Q4 2025 per SPRC's latest filing, from $182000.0 in the prior quarter.
- Over five years, Total Debt peaked at $4.2 million in Q4 2024 and troughed at $182000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 9.34 Bn |
| 10 | SciSparc | 807,202.50 | 807,202.50 | - | 356,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 356,000.00 |
| Jun 30, 2025 | 182,000.00 |
| Dec 31, 2024 | 4.22 Mn |
| Dec 31, 2020 | 188,000.00 |
| Jun 30, 2020 | 61,000.00 |
| Jun 30, 2019 | 993,000.00 |
| Dec 31, 2018 | 779,000.00 |